Thanks Tony, Going back to the AGM presentation, Phylogica hopes to position itself for a trade sale through the development of its in-house programs; CD40L is a key program.
"Be assured there is plenty of big Pharma interest in CD40L. Prospective Pharma partners for CD40L want in vitro data rather than anything more extensive in animal models. We envisage 6-12 months for the data," Phylogica management, your post 26 February , 2013.
The note from management highlights a) there is plenty of interest and b) the data for evaluation by Big Pharma parties will be available in 6-12 months.
A trade sale could conceivably follow the evaluation of the data for the CD40L program. Its particularly interesting that Big Pharma only want the in vitro data "for benchmarks required to compete with the new generation of anti-CD40L therapies that have recently entered Phase I/II clinical trial". There is a powerful suggestion that the available in vivo data has already established a therapeutic benefit. In fact, clinical trials may be possible within a relatively short time frame.
Regards,
Wayne.
PYC Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)